Healthcare firm AstraZeneca Pharma on Thursday said it has received approval from India's drug regulator to market Acalabrutinib 100mg capsules, a medicine for treatment of chronic lymphocytic leukaemia.
"This is to inform that AstraZeneca Pharma India Limited has received import and market permission...from the Drugs Controller General of India for Acalabrutinib 100mg capsules," the company said in aBSE filing.
The receipt of this permission paves way for the launch of the capsules in India, subject to the receipt of related statutory approvals and licences, it said.
The capsule "is indicated for treatment of patients with chronic lymphocytic leukaemia/ small lymphocytic lymphoma", it added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app